
Cybin (CYBN) Stock Forecast & Price Target
Cybin (CYBN) Analyst Ratings
Bulls say
Cybin Inc is advancing its clinical-stage neuropsychiatric programs with notable commercial readiness efforts, positioning itself strategically for scalability in interventional psychiatry. The company's strong clinical execution and financial enhancements have established a solid foundation ahead of pivotal clinical readouts expected in 2026, reinforcing confidence in its therapeutic advancements. Additionally, the completion of enrollment in the Phase 2 CYB004 generalized anxiety disorder trial and continued progress in the Phase 3 CYB003 major depressive disorder program underscore Cybin's commitment to delivering innovative treatments for mental health issues.
Bears say
Cybin Inc's stock faces a negative outlook primarily due to the risks associated with developing neuropsychiatric therapies, where trial failures can arise from various unforeseen issues. The company has experienced a reduction in its discounted cash flow (DCF) valuation based on dilution from recent fundraising efforts, which has led to a downward adjustment of its price target. Additionally, unresolved concerns regarding the safety, efficacy, and regulatory approval of Cybin's psychedelic compounds further undermine confidence in the potential success of its product pipeline.
This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.
Cybin (CYBN) Analyst Forecast & Price Prediction
Start investing in Cybin (CYBN)
Order type
Buy in
Order amount
Est. shares
0 shares